QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Altor BioScience
Terminated
Patient population did not benefit from single agent treatment.
Other terminated trials from Altor BioScience
Other Relapsed or Refractory Multiple Myeloma trials with similar outcome
This PHASE1/PHASE2 trial investigates Relapsed or Refractory Multiple Myeloma and is currently terminated or withdrawn. Altor BioScience leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Sep 2017 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Aug 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Altor BioScience
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .